Determinazione di Tau, p-Tau e beta amiloide 1-42 in pazienti affetti da malattia di Alzheimer e demenza frontotemporale

Translated title of the contribution: Tau, p-Tau and beta amiloid 1-42 concentrations in Alzheimer and frontotemporal dementia patients

Matteo Zabeo, F. De Rino, F. Rispoli, F. Somalvico, E. Longhi, M. Franceschi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Alzheimer's disease (AD) is the most common form of dementia and its clinical differentiation from fronto-temporal dementia (FTD) is often difficult. Cerebro-spinal fluid (CSF) Tau, p-Tau and β amyloid 1-42 (βA 1-42) concentrations seem to be a valid support in clinical diagnosis. Our goal is to analyse the CSF Tau, p-Tau e βA 1-42 concentrations and their ratio to identify early-onset AD from subjects with FTD. Methods. 82 CSF samples collected with lumbar puncture: 43 from subjects with probable AD (NINCDS-ADRA criteria) and 39 from subjects with probable FTD (Neary criteria). Tau, p-Tau and βA 1-42 concentrations have been tested with ELISA test (Innotest, Innogenetics, Ghent, Belgium). Results. Only βA 1-42 and p-Tau concentrations have shown statistically significant differences between AD and FTD subjects (βA 1-42 AD: 383±169 ng/L, FTD: 510±288 ng/L, p=0.05 and p-Tau AD: 92±45 ng/L, FTD: 70±46 ng/L, p=0.002). The graphic combination of Tau, p-Tau e βA 1-42 has confirmed the clinical suspect of AD in 34/43 samples (sensitivity: 79%, specificity: 69%). FTD clinical suspect has been confirmed in 19/39 samples (sensitivity: 49%, specificity: 88%). Our data indicate the ratio βA 1-42/Tau and βA 1-42/pTau as clinically significant to discriminate AD from FTD (p=0.002 and p1-42 concentrations and their ratio, although tested on a small number of samples, seems to be a further support to assist clinician in confirming a suspected AD or to exclude AD in a case of clinical suspect of FTD.

Original languageItalian
Pages (from-to)259-263
Number of pages5
JournalRivista Italiana della Medicina di Laboratorio
Volume4
Issue number4
Publication statusPublished - 2008

Fingerprint

Frontotemporal Dementia
Dementia
Alzheimer Disease
Cerebrospinal Fluid
Fluids
Sensitivity and Specificity
Spinal Puncture
Belgium
Amyloid
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Biochemistry, medical
  • Medical Laboratory Technology

Cite this

Determinazione di Tau, p-Tau e beta amiloide 1-42 in pazienti affetti da malattia di Alzheimer e demenza frontotemporale. / Zabeo, Matteo; De Rino, F.; Rispoli, F.; Somalvico, F.; Longhi, E.; Franceschi, M.

In: Rivista Italiana della Medicina di Laboratorio, Vol. 4, No. 4, 2008, p. 259-263.

Research output: Contribution to journalArticle

@article{30762b1f16f346359208256082a11be1,
title = "Determinazione di Tau, p-Tau e beta amiloide 1-42 in pazienti affetti da malattia di Alzheimer e demenza frontotemporale",
abstract = "Background. Alzheimer's disease (AD) is the most common form of dementia and its clinical differentiation from fronto-temporal dementia (FTD) is often difficult. Cerebro-spinal fluid (CSF) Tau, p-Tau and β amyloid 1-42 (βA 1-42) concentrations seem to be a valid support in clinical diagnosis. Our goal is to analyse the CSF Tau, p-Tau e βA 1-42 concentrations and their ratio to identify early-onset AD from subjects with FTD. Methods. 82 CSF samples collected with lumbar puncture: 43 from subjects with probable AD (NINCDS-ADRA criteria) and 39 from subjects with probable FTD (Neary criteria). Tau, p-Tau and βA 1-42 concentrations have been tested with ELISA test (Innotest, Innogenetics, Ghent, Belgium). Results. Only βA 1-42 and p-Tau concentrations have shown statistically significant differences between AD and FTD subjects (βA 1-42 AD: 383±169 ng/L, FTD: 510±288 ng/L, p=0.05 and p-Tau AD: 92±45 ng/L, FTD: 70±46 ng/L, p=0.002). The graphic combination of Tau, p-Tau e βA 1-42 has confirmed the clinical suspect of AD in 34/43 samples (sensitivity: 79{\%}, specificity: 69{\%}). FTD clinical suspect has been confirmed in 19/39 samples (sensitivity: 49{\%}, specificity: 88{\%}). Our data indicate the ratio βA 1-42/Tau and βA 1-42/pTau as clinically significant to discriminate AD from FTD (p=0.002 and p1-42 concentrations and their ratio, although tested on a small number of samples, seems to be a further support to assist clinician in confirming a suspected AD or to exclude AD in a case of clinical suspect of FTD.",
keywords = "β amiloid, Alzheimer, p-Tau, Tau",
author = "Matteo Zabeo and {De Rino}, F. and F. Rispoli and F. Somalvico and E. Longhi and M. Franceschi",
year = "2008",
language = "Italian",
volume = "4",
pages = "259--263",
journal = "Rivista Italiana della Medicina di Laboratorio",
issn = "1825-859X",
publisher = "SIMeL Societa Italiana di Medicina di Laboratorio",
number = "4",

}

TY - JOUR

T1 - Determinazione di Tau, p-Tau e beta amiloide 1-42 in pazienti affetti da malattia di Alzheimer e demenza frontotemporale

AU - Zabeo, Matteo

AU - De Rino, F.

AU - Rispoli, F.

AU - Somalvico, F.

AU - Longhi, E.

AU - Franceschi, M.

PY - 2008

Y1 - 2008

N2 - Background. Alzheimer's disease (AD) is the most common form of dementia and its clinical differentiation from fronto-temporal dementia (FTD) is often difficult. Cerebro-spinal fluid (CSF) Tau, p-Tau and β amyloid 1-42 (βA 1-42) concentrations seem to be a valid support in clinical diagnosis. Our goal is to analyse the CSF Tau, p-Tau e βA 1-42 concentrations and their ratio to identify early-onset AD from subjects with FTD. Methods. 82 CSF samples collected with lumbar puncture: 43 from subjects with probable AD (NINCDS-ADRA criteria) and 39 from subjects with probable FTD (Neary criteria). Tau, p-Tau and βA 1-42 concentrations have been tested with ELISA test (Innotest, Innogenetics, Ghent, Belgium). Results. Only βA 1-42 and p-Tau concentrations have shown statistically significant differences between AD and FTD subjects (βA 1-42 AD: 383±169 ng/L, FTD: 510±288 ng/L, p=0.05 and p-Tau AD: 92±45 ng/L, FTD: 70±46 ng/L, p=0.002). The graphic combination of Tau, p-Tau e βA 1-42 has confirmed the clinical suspect of AD in 34/43 samples (sensitivity: 79%, specificity: 69%). FTD clinical suspect has been confirmed in 19/39 samples (sensitivity: 49%, specificity: 88%). Our data indicate the ratio βA 1-42/Tau and βA 1-42/pTau as clinically significant to discriminate AD from FTD (p=0.002 and p1-42 concentrations and their ratio, although tested on a small number of samples, seems to be a further support to assist clinician in confirming a suspected AD or to exclude AD in a case of clinical suspect of FTD.

AB - Background. Alzheimer's disease (AD) is the most common form of dementia and its clinical differentiation from fronto-temporal dementia (FTD) is often difficult. Cerebro-spinal fluid (CSF) Tau, p-Tau and β amyloid 1-42 (βA 1-42) concentrations seem to be a valid support in clinical diagnosis. Our goal is to analyse the CSF Tau, p-Tau e βA 1-42 concentrations and their ratio to identify early-onset AD from subjects with FTD. Methods. 82 CSF samples collected with lumbar puncture: 43 from subjects with probable AD (NINCDS-ADRA criteria) and 39 from subjects with probable FTD (Neary criteria). Tau, p-Tau and βA 1-42 concentrations have been tested with ELISA test (Innotest, Innogenetics, Ghent, Belgium). Results. Only βA 1-42 and p-Tau concentrations have shown statistically significant differences between AD and FTD subjects (βA 1-42 AD: 383±169 ng/L, FTD: 510±288 ng/L, p=0.05 and p-Tau AD: 92±45 ng/L, FTD: 70±46 ng/L, p=0.002). The graphic combination of Tau, p-Tau e βA 1-42 has confirmed the clinical suspect of AD in 34/43 samples (sensitivity: 79%, specificity: 69%). FTD clinical suspect has been confirmed in 19/39 samples (sensitivity: 49%, specificity: 88%). Our data indicate the ratio βA 1-42/Tau and βA 1-42/pTau as clinically significant to discriminate AD from FTD (p=0.002 and p1-42 concentrations and their ratio, although tested on a small number of samples, seems to be a further support to assist clinician in confirming a suspected AD or to exclude AD in a case of clinical suspect of FTD.

KW - β amiloid

KW - Alzheimer

KW - p-Tau

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=58849098624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849098624&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:58849098624

VL - 4

SP - 259

EP - 263

JO - Rivista Italiana della Medicina di Laboratorio

JF - Rivista Italiana della Medicina di Laboratorio

SN - 1825-859X

IS - 4

ER -